This may in part be due to the fact that most chemoprevention strategies to date (that is, selective estrogen response modulators (SERMs) and aromatase inhibitors) target estrogen, and are thus limited in their efficacy for hormonally responsive breast cancer. Here, CYP19A1 is linked to breast carcinoma.